Sucanon^TM acts to increase the body's ability to utilize its insulin, resulting in improved metabolism and an enhanced sense of well-being for the patient. This increased insulin sensitivity results in decreased blood sugar levels in those suffering from Type II Diabetes. Sucanon^TM is one of only three drugs approved anywhere in the world, belonging to a new category of drugs called "insulin sensitizers".

1. Insulin binding to receptors and entering the cell, (which is impeded in NIDDM patients), is essential for the uptake of glucose	2. SucanonTM increases the binding of insulin to its receptors	3. SucanonTM increases the internalization of insulin	4. As a result, SucanonTM increases the intracellular level of insulin, which then increases the uptake of glucose

Clinical studies involving three hospitals and 1,500 patients were completed in China. A high satisfaction rate was indicated by a post-clinical trial poll and by follow-up data on 7,600 patients, reported in 2001. In preparation for regulatory applications to be made throughout Latin America, a supplementary and confirming clinical trial was carried out in Brazil.

The drug has received regulatory approval in Mexico and Peru. Sales in Mexico began in early 2005 under the tradename "Sucanon". Sales in Peru are projected to begin in 2006, under the trade name "Glucanin". Production of key ingredients of the drug is carred out at Biotech's plant in suburban Vancouver; talbeting and packaging is done in Mexico City for the Mexican market and is projected to be done in Lima for the Peru market.

Mexico is the eighth largest pharmaceutical market and one of the largest diabetic markets in the world.